Novel Antimicrobial Dressing in Peripheral Intravenous Catheters (PIVCs)

Not Applicable

Recruiting

• Conditions: Catheter Infection; Vascular Access Complication; Device Related Sepsis; Catheter Complications; Wound of Skin; Device Related Infection; Catheter Related Complication; Wound; Occlusive Dressings; Device Site Reactions
• Interventions: Device: Standard bordered polyurethane dressing; Device: Chlorhexidine gluconate impregnated bordered polyurethane dressing

• Registration Number: NCT05741866
• Lead Sponsor: The University of Queensland

Brief Summary

The goal of this clinical trial is to compare a chlorhexidine impregnated dressing for peripheral intravenous catheters (PIVCs) to the standard dressing currently used in general medical and surgical inpatient wards.

The main questions it aims to answer are:

* Study Feasibility

* Occurrence of infectious complications related to the PIVC

Participants will be randomly allocated to receive either of the below dressings to cover and secure their PIVC:

* The standard dressing used at their hospital, or

* The intervention dressing which has Chlorhexidine gluconate (CHG) on it

Researchers will compare standard and CHG dressings to see if the presence of CHG improves the occurrence of infectious complications related to the PIVC.

Detailed Description

This study is a multi-centre, two-arm, parallel group adaptive Randomized Controlled Trial (RCT) to test effectiveness, cost-effectiveness, and safety of 3M™ Tegaderm™ Antimicrobial IV Advanced Securement dressings with standard polyurethane dressings for PIVCs. The study has two phases. Phase I is an internal feasibility pilot for which only feasibility outcomes will be considered (no analysis). At this time (n=300) an independent Data Safety Monitoring Committee (DSMC) comprised of a biostatistician, physician and expert trialist will review pre-defined blinded analyses of feasibility and safety data. Phase II will then go ahead if feasibility outcomes are satisfactory, and will involve continuation of trial recruitment to complete a definitive RCT. If Phase II does not proceed then all outcomes will be reported at the end of Phase I.

Setting and sample:

Australia: The ProP Trial will be undertaken in the general medical/surgical and oncology/hematology departments at the Queensland Children's Hospital (QCH; Site 1), and the general medical/surgical departments at the Royal Brisbane and Women's Hospital (RBWH; Site 2) Brisbane, Australia. These are both large quaternary referral teaching hospitals (Site 1: 359 beds; Site 2: 929 beds).

France: The ProP Trial will be undertaken in the University Hospital of Poitiers (PUH), a large referral teaching hospital with 959 acute beds. Patients will be recruited at the Emergency Department, before being admitted to medical wards.

Sample size:

Phase 1: The investigators will recruit 300 patients (200 Australia and 100 France) with 150 patients per arm. This sample size is not determined by statistical power but to test protocol feasibility and gain estimates of effect to inform a sample size calculation for a full trial. The investigators aim to recruit 300 patients over 16 weeks (19 per week).

Phase 2: The investigators will continue recruitment to the sample size recommended by the DSMC and the Trial Steering Committee. The investigators anticipate this will be no more than a sample of 2624 patients (1312/group) which would have 90% power to detect an absolute 5% reduction in the primary outcome from 22% to 17% (2-way alpha 0.05) (http://powerandsamplesize.com/calculators).

Study Timeline

• Status Verified: 2022-11
• Study First Submitted: 2022-12-15
• Study First Submitted QC: 2023-02-14
• Study First Posted: 2023-02-23
• Study Start: 2023-05-03
• Last Update Submitted: 2023-08-16
• Last Update Posted: 2023-08-21
• Primary Completion: 2023-11
• Study Completion: 2023-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• PIVC to be inserted with expected dwell >48 hours
• Provided written and informed consent (patient or carer)

Australia only

• ≥6 years of age (due to size of dressing)

France only

• ≥18 years of age

Exclusion Criteria

• Burned, non-intact or scarred skin at the insertion site
• Known allergy to CHG or transparent dressing adhesives
• Palliative care patients on end-of-life pathway
• Patient who has already participated in the study
• Placement of a PIVC in an emergency, that does not allow the usual rules of hygiene for insertion to be adhered to.

Additional exclusions to Australian study only

• Non-English-speaking patients without interpreter
• Under the care of Child and Family Services and unable to gain consent from case worker (paediatric patients)

Additional exclusions to French study only

• Patients not benefiting from the French Social Security scheme or not benefiting from it through a third party,
• Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, adults under legal protection.
• Known pregnant or breastfeeding women
• Predictably difficult vascular access (IV drug addiction, obesity)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control	Standard bordered polyurethane dressing	Bordered Polyurethane Dressing
Intervention	Chlorhexidine gluconate impregnated bordered polyurethane dressing	CHG Bordered Polyurethane Dressing

Primary Outcome Measures

Name	Time	Method
Feasibility for a definitive RCT	On completion of 300 participants	The feasibility of conducting a definitive RCT will be assessed against the following criteria: i. Study Eligibility as per inclusion/exclusion criteria (≥80% of screened participants will be eligible for study inclusion) ii. Participant Recruitment onto study (≥80% of eligible participants will provide informed consent to participate in the study) iii. Retention of study participants (\<10% will be lost to follow up) iv. Protocol fidelity of study participants (≥80% will receive the allocated intervention) v. Missing data for primary outcome 2 (\<5% of primary outcome 2 data will be unable to be collected) vi. Satisfaction of participants/parents and staff (\<10% report "low" satisfaction with the intervention arm (rated low/medium/high) vii. An estimate of catheter-related infectious complications (defined as per primary outcome 2) in the control group that indicate a fully powered multi-site RCT is achievable
Catheter-related infectious complications and phlebitis	Daily until 48hours after study PIVC is removed.	Proportion of patients with a composite measure of PIVC Colonization; PIVC local infection; PIVC-associated Bloodstream Infection (BSI) and Phlebitis. These measures are defined below in secondary outcomes.; If patients meet more than one of the following \[e.g., phlebitis and PIVC local infection\], both will be collected however only counted once for the composite measure.

Secondary Outcome Measures

Name	Time	Method
Skin colonization	On study PIVC removal	Reported semi-quantitatively as scant, 1+, 2+, 3.; PIVC skin swabs will be collected based on Nurse and laboratory availability at time of PIVC removal.
Serious adverse event	Daily until 48hours after study PIVC is removed.	Proportion of patients with anaphylactic reaction to CHG in dressing; or mortality related to PIVC infection.; Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record.
Patient reported experience measures of the dressing	Daily until 48hours after study PIVC is removed.	Proportion of participants/parents who report their satisfaction with the dressing rated low/medium/high with respective prompts of: 1. "I'd rather use a different dressing next time"; 2. "The dressing was ok, but I'm happy to try other types"; 3. "It was a really good dressing and I'd like to use this one again"; A Patient-Reported Experience Measure survey will be conducted on study PIVC removal.; Patient's will have the opportunity to comment on the dressing and their satisfaction with it at any time during study participation.
PIVC tip colonization	Daily until 48hours after study PIVC is removed.	\>15 cfu of a pathogen semi-quantitative method, or ≥1000 cfu of a pathogen per mL broth method.; PIVC tips will be collected based on Nurse and laboratory availability at time of PIVC removal.
PIVC device failure	Daily until 48hours after study PIVC is removed.	Proportion of patients, a composite of infiltration/ extravasation, blockage/occlusion (with/without leakage), phlebitis (as defined above), thrombosis, dislodgement (complete/partial) or infection (as defined above).; Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record.
PIVC local infection without Bloodstream Infection (BSI)	Daily until 48hours after study PIVC is removed.	Proportion of patients with a PIVC local infection without BSI as defined by NHSN 2021 criteria for Cardiovascular System VASC-Arterial or Venous Infection (CVS-VASC); adult and child/infant criteria.; Collected daily by either the research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record and microbiology results.
Phlebitis	Daily until 48hours after study PIVC is removed.	Either pain or tenderness \[\>1 on a scale of 0 to 10\]), or at least 2 of erythema, swelling, purulence or palpable cord.; Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record.
Adverse skin event	Daily until 48hours after study PIVC is removed.	Proportion of patients with skin complications at PIVC site: mechanical (e.g. pressure injury, skin tears, blisters, bruising) or inflammatory complications (e.g. contact/allergic dermatitis, skin rash, pruritus).; Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record.
PIVC-associated Bloodstream Infection	Daily until 48hours after study PIVC is removed.	Proportion of patients with a laboratory Confirmed Bloodstream Infection, as defined by NHSN 2021 adult and infant criteria; Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record and microbiology results.
Cost effectiveness	Until discharge.	Direct and indirect healthcare costs to the health system, including cost per complication avoided.; Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record and microbiology results.; A random subset of 15% of participants will have all subsequent devices recorded until completion of treatment for the participant's current admission. Date of discharge will be recorded for all participants to calculate length of stay.
Dressing durability	Daily until study PIVC is removed.	Proportion of patients with dressing durability assessed as: (i) the dressing remains adhered to the skin on all four sides until PIVC removal; and, (ii) accidental dislodgement (excluding patients who deliberately remove their PIVC).; Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record.
Clinician reported experience measures of the dressing including application and removal	Daily until 48hours after study PIVC is removed.	Proportion of clinicians who report their satisfaction with the dressing rated low/medium/high with respective prompts of: 1. "I'd rather use a different dressing next time"; 2. "The dressing was ok, but I'm happy to try other types"; 3. "It was a really good dressing and I'd like to use this one again"; Collected opportunistically between dressing application to 48 hours after study PIVC removal.

Trial Locations

Locations (3)

Queensland Children's Hospital; 🇦🇺 South Brisbane, Queensland, Australia

Royal Brisbane and Women's Hospital; 🇦🇺 Herston, Queensland, Australia

University Hospital of Poitiers; 🇫🇷 Poitiers, Nouvelle-Aquitaine, France